Biotech & AI drug discoverySTAT — Biotech

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

Shares of ProMis Neurosciences, a developer of a treatment for Alzheimer's disease, sold off sharply last week. The article examines the reason behind the decline and whether that explanation holds up to scrutiny.

AI summary · generated only from source feed metadata; consult original

Source published2026-11-05T11:30:00+00:00

Published here2026-11-05T11:44:39+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/11/05/promis-neurosciences-alzheimers-disease-acumen-vertex-kidney-drug/

Original headline

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.